BTG Pactual hires Charles Rosier for European business

BTG Pactual hires Charles Rosier for European business

He switched jobs many times while pursuing his profession in the industry as an investment banker. He is interested in numerous things like studies, extreme sports, handling environmentally-friendly activities and culture. charles rosier (Visiter le site Efinancialnews.com) gained his first employment in 1996 at Lehman Brothers and joined UBS Warburg Investment Bank prior to going to Goldman Sachs Bank where he was assigned to the finance department.

Charles Rosier's Chosen Career Path

Charles Rosier became a member of BTG Pactual in August 2010. He became partners with an investment bank in Latin America: BTG Pactual. In 1999, Goldman Sachs (GMS) offered Charles Rosier a job. He accepted the offer and joined as their Managing Director. There are approximately 2,500 workers currently hired at BTG Pactual, which has 30 years of experience in the market.

Charles Rosier's Environmental Projects

Charles Rosier gave his support to Luci MPOWERD, being the perfect source of clean and renewable-energy. The company was able to create innovative solutions because of the support he gave. To develop lanterns and other energy solutions, Charles Rosier extended his assistance by making an investment in MPOWERD. With this, MPOWERD delivered these solutions to more than 25 poor nations around the world. Economical LED lanterns is a project of MPOWERD. These are being delivered to poor countries to provide them with cost-effective energy solutions.

Because of the capital he invested, the study on depression, strokes and other serious illnesses was performed at Mapreg, a Paris-based laboratory. Mapreg is a pharmaceutical company led by Professor Etienne Baulieu. They were funded by Charles Rosier when he started to conduct healthcare projects. The project was a test to find a treatment for strokes that can harm the spinal cord. Charles Rosier was its major investor. He helped Baulieu and his colleagues to develop a new drug by financing the research.